ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Rochester, MN, USA:

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Rochester, Minnesota, United States and 176 other locations

study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer.The names of the study drugs involved in this s...

Enrolling
Ovarian Clear Cell Carcinoma
Gynecologic Cancer
Drug: Pembrolizumab
Drug: Lenvatinib

Phase 2

Elizabeth K. Lee MD

Rochester, Minnesota, United States and 2 other locations

within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single ...

Enrolling
Ovarian Neoplasms
Drug: Niraparib
Drug: Paclitaxel

Phase 1, Phase 2

Tesaro
Tesaro

Rochester, Minnesota, United States and 24 other locations

This phase II trial studies how well pembrolizumab works in treating participants with ovarian cancer that has come back after prev...

Active, not recruiting
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Biological: Pembrolizumab

Phase 2

Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center

Rochester, Minnesota, United States and 2 other locations

in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian...

Enrolling
Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Platinum-refractory Ovarian Carcinoma
Biological: pembrolizumab
Biological: TILT-123

Phase 1

TILT Biotherapeutics

Rochester, Minnesota, United States and 2 other locations

of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus* The study will ...

Enrolling
Recurrent Primary Peritoneal Cancer
Recurrent Ovarian Cancer
Drug: REGN4018
Drug: Sarilumab

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Rochester, Minnesota, United States and 49 other locations

in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, wh...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

Phase 3

ImmunoGen
ImmunoGen

Rochester, Minnesota, United States and 207 other locations

This study, ELU- FRα-1, is focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors con...

Enrolling
Ovarian Neoplasms
Ovarian Cancer Stage
Drug: ELU001

Phase 1, Phase 2

Elucida Oncology

Rochester, Minnesota, United States and 17 other locations

The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer...

Enrolling
Ovarian Neoplasms
Colon Cancer
Diagnostic Test: xT CDx with HLA-LOH Assay
Biological: A2B694

Phase 1, Phase 2

A2 Biotherapeutics

Rochester, Minnesota, United States and 8 other locations

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian...

Active, not recruiting
Low Grade Serous Carcinoma
Drug: Ribociclib
Drug: Letrozole

Phase 2

Gynecologic Oncology Group (GOG)

Rochester, Minnesota, United States and 26 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems